ロード中...
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR-T cells
Immunotherapy with chimeric antigen receptor (CAR)-engineered T cells can be effective against advanced malignancies. CAR-T cells are ‘living drugs’ that require technologies to enable physicians (and patients) to maintain control over the infused cell product. Here, we demonstrate that the tyrosine...
保存先:
| 出版年: | Sci Transl Med |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523030/ https://ncbi.nlm.nih.gov/pubmed/31270272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aau5907 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|